Actively Recruiting
Surrogate Markers of Response to New Therapies in Cystic Fibrosis Patients
Led by Hôpital Necker-Enfants Malades · Updated on 2024-03-12
75
Participants Needed
1
Research Sites
543 weeks
Total Duration
On this page
Sponsors
H
Hôpital Necker-Enfants Malades
Lead Sponsor
A
Association Mucoviscidose-ABCF2
Collaborating Sponsor
AI-Summary
What this Trial Is About
The purpose of this study is to determine which biological marker, or association of biological markers, best predict clinical response of cystic fibrosis patients to CFTR modulators.
CONDITIONS
Official Title
Surrogate Markers of Response to New Therapies in Cystic Fibrosis Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Cystic fibrosis patients treated by CFTR modulators (Ivacaftor or the association Ivacaftor-Lumacaftor)
- Cystic fibrosis patients non treated by CFTR modulators
- Patients in whom cystic fibrosis diagnosis has been suspected, but excluded by physiological and genetic investigations
You will not qualify if you...
- Pregnant or lactating women
- Contraindication to nasal swab
- Contraindication to rectal biopsy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Necker Hospital
Paris, France, 75014
Actively Recruiting
Research Team
I
Isabelle Sermet, MD, PhD
CONTACT
J
Jean-Louis Pérignon, MD, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
BASIC_SCIENCE
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here